Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas

References

• Janz TA, Neskey DM, Nguyen SA, Lentsch EJ. Is the incidence of anaplastic thyroid cancer increasing: a population based epidemiology study. World J Otorhinolaryngol Head Neck Surg. 2019;5(1):34–40. doi:10.1016/j.wjorl.2018.05.006
   PubMedGoogle Scholar
• Amphlett B, Lawson Z, Abdulrahman GO, et al. Recent trends in the incidence, geographical distribution, and survival from thyroid cancer in Wales, 1985–2010. Thyroid. 2013;23(11):1470–1478. doi:10.1089/thy.2012.0573
   PubMed Web of Science ®Google Scholar
• de Ridder M, Nieveen van Dijkum E, Engelsman A, Kapiteijn E, Klumpen HJ, Rasch CRN. Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. Eur J Endocrinol. 2020;183(2):203–209. doi:10.1530/EJE-20-0080
   PubMed Web of Science ®Google Scholar
• Hvilsom GB, Londero SC, Hahn CH, et al. Anaplastic thyroid carcinoma in Denmark 1996–2012: a national prospective study of 219 patients. Cancer Epidemiol. 2018;53:65–71. doi:10.1016/j.canep.2018.01.011
   PubMed Web of Science ®Google Scholar
• Wendler J, Kroiss M, Gast K, et al. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol. 2016;175(6):521–529. doi:10.1530/EJE-16-0574
   PubMed Web of Science ®Google Scholar
• Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC research consortium of Japan cohort study of 677 patients. World J Surg. 2012;36(6):1247–1254. doi:10.1007/s00268-012-1437-z
   PubMed Web of Science ®Google Scholar
• Xu B, Fuchs T, Dogan S, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid. 2020;30(10):1505–1517. doi:10.1089/thy.2020.0086
   PubMed Web of Science ®Google Scholar
• De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(4):1137–1143. doi:10.1016/j.ijrobp.2004.05.032
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Williams MD, Gunn GB, et al. Facilitating anaplastic thyroid cancer specialized treatment: a model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head Neck. 2017;39(7):1291–1295. doi:10.1002/hed.24784
   PubMed Web of Science ®Google Scholar
• Capdevila J, Wirth LJ, Ernst T, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38(23):2620–2627. doi:10.1200/JCO.19.02727
   PubMed Web of Science ®Google Scholar
• Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000–2019. JAMA Oncol. 2020;6(9):1397–1404. doi:10.1001/jamaoncol.2020.3362
   PubMed Web of Science ®Google Scholar
• Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644–660. doi:10.1038/nrendo.2017.76
   PubMed Web of Science ®Google Scholar
• Bible KC, Kebebew E, Brierley J, et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337–386. doi:10.1089/thy.2020.0944
   PubMed Web of Science ®Google Scholar
• Ryder M, Gild M, Hohl TM, et al. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One. 2013;8(1):e54302. doi:10.1371/journal.pone.0054302
   PubMed Web of Science ®Google Scholar
• Ito K, Hanamura T, Murayama K, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck. 2012;34(2):230–237. doi:10.1002/hed.21721
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Dadu R, Iyer P, et al. Acquired secondary RAS Mutation in BRAF(V600E)-Mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid. 2020;30(9):1288–1296. doi:10.1089/thy.2019.0514
   PubMed Web of Science ®Google Scholar
• Sparano C, Godbert Y, Attard M, et al. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. Endocr Relat Cancer. 2021;28(1):15–26. doi:10.1530/ERC-20-0106
   PubMed Web of Science ®Google Scholar
• Gleiter H. Nanostructured materials: basic concepts and microstructure. Acta Mater. 2000;48:1–29. doi:10.1016/S1359-6454(99)00285-2
   Web of Science ®Google Scholar
• Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054–1067. doi:10.1056/NEJMra1501993
   PubMed Web of Science ®Google Scholar
• Webster TJ. Nanomedicine: what’s in a definition?. Int J Nanomedicine. 2006;1(2):115–116. doi:10.2147/nano.2006.1.2.115
   PubMed Web of Science ®Google Scholar
• Martinelli C, Pucci C, Ciofani G. Nanostructured carriers as innovative tools for cancer diagnosis and therapy. APL Bioeng. 2019;3(1):011502. doi:10.1063/1.5079943
   PubMed Web of Science ®Google Scholar
• Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg. 2019;6(1):23. doi:10.1186/s40580-019-0193-2
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou Y, Liu L, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193. doi:10.3389/fmolb.2020.00193
   PubMed Web of Science ®Google Scholar
• Zein R, Sharrouf W, Selting K. Physical properties of nanoparticles that result in improved cancer targeting. J Oncol. 2020;2020:5194780. doi:10.1155/2020/5194780
   PubMed Web of Science ®Google Scholar
• Huynh E, Zheng G. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomedicine. 2015;10(13):1993–1995. doi:10.2217/nnm.15.86
   PubMed Web of Science ®Google Scholar
• Thomas OS, Weber W. Overcoming physiological barriers to nanoparticle delivery-are we there yet?. Front Bioeng Biotechnol. 2019;7:415. doi:10.3389/fbioe.2019.00415
   PubMed Web of Science ®Google Scholar
• Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38. doi:10.1016/j.addr.2018.07.007
   PubMed Web of Science ®Google Scholar
• Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521–535. doi:10.1007/s00401-017-1769-8
   PubMed Web of Science ®Google Scholar
• Celano M, Calvagno MG, Bulotta S, et al. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer. 2004;4:63. doi:10.1186/1471-2407-4-63
   PubMed Web of Science ®Google Scholar
• Cristiano MC, Cosco D, Celia C, et al. Anticancer activity of all-trans retinoic acid-loaded liposomes on human thyroid carcinoma cells. Colloids Surf B Biointerfaces. 2017;150:408–416. doi:10.1016/j.colsurfb.2016.10.052
   PubMed Web of Science ®Google Scholar
• Gao XJ, Li AQ, Zhang X, Liu P, Wang J, Cai X. Thyroid-stimulating hormone (TSH)-armed polymer–lipid nanoparticles for the targeted delivery of cisplatin in thyroid cancers: therapeutic efficacy evaluation. RSC Adv. 2015;5:106413–106420. doi:10.1039/C5RA12588J
   Web of Science ®Google Scholar
• Li Q, Zhang L, Lang J, et al. Lipid-Peptide-mRNA nanoparticles augment radioiodine uptake in anaplastic thyroid cancer. Adv Sci. 2023;10(3):e2204334. doi:10.1002/advs.202204334
   Web of Science ®Google Scholar
• Maroof H, Islam F, Dong L, et al. Liposomal delivery of miR-34b-5p induced cancer cell death in thyroid carcinoma. Cells. 2018;7(12):265. doi:10.3390/cells7120265
   PubMed Web of Science ®Google Scholar
• Wang Q, Sui G, Wu X, et al. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics. Acta Biomater. 2020;102:367–383. doi:10.1016/j.actbio.2019.11.043
   PubMed Web of Science ®Google Scholar
• Lombardo GE, Maggisano V, Celano M, et al. Anti-hTERT siRNA-loaded nanoparticles block the growth of anaplastic thyroid cancer xenograft. Mol Cancer Ther. 2018;17(6):1187–1195. doi:10.1158/1535-7163.MCT-17-0559
   PubMed Web of Science ®Google Scholar
• Liu Y, Gunda V, Zhu X, et al. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer. Proc Natl Acad Sci U S A. 2016;113(28):7750–7755. doi:10.1073/pnas.1605841113
   PubMed Web of Science ®Google Scholar
• Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017;6(1):44. doi:10.1186/s40169-017-0175-0
   PubMed Web of Science ®Google Scholar
• Heydari Z, Mohebbi-Kalhori D, Afarani MS. Engineered electrospun polycaprolactone (PCL)/octacalcium phosphate (OCP) scaffold for bone tissue engineering. Mater Sci Eng C Mater Biol Appl. 2017;81:127–132. doi:10.1016/j.msec.2017.07.041
   PubMed Web of Science ®Google Scholar
• Zhang R, Zhang Y, Tan J, et al. Antitumor Effect of (131)I-Labeled Anti-VEGFR2 targeted mesoporous silica nanoparticles in anaplastic thyroid cancer. Nanoscale Res Lett. 2019;14(1):96. doi:10.1186/s11671-019-2924-z
   PubMedGoogle Scholar
• Zhang X, Yan Z, Meng Z, et al. Radionuclide (131)I-labeled albumin-indocyanine green nanoparticles for synergistic combined radio-photothermal therapy of anaplastic thyroid cancer. Front Oncol. 2022;12:889284. doi:10.3389/fonc.2022.889284
   PubMed Web of Science ®Google Scholar
• Zhang C, Chai J, Jia Q, et al. Evaluating the therapeutic efficacy of radiolabeled BSA@CuS nanoparticle-induced radio-photothermal therapy against anaplastic thyroid cancer. IUBMB Life. 2022;74(5):433–445. doi:10.1002/iub.2601
   PubMed Web of Science ®Google Scholar
• Liu Y, Ai K, Lu L. Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields. Chem Rev. 2014;114(9):5057–5115. doi:10.1021/cr400407a
   PubMed Web of Science ®Google Scholar
• Wu D, Duan HX, Guan QQ, et al.. Mesoporous polydopamine carrying manganese carbonyl responds to tumor microenvironment for multimodal imaging-guided cancer therapy. Adv Funct Mater. 2019;29:1900095. doi:10.1002/adfm.201900095
   Web of Science ®Google Scholar
• Qi C, Fu LH, Xu H, Wang TF, Lin J, Huang P. Melanin/polydopamine-based nanomaterials for biomedical applications. Sci China Chem. 2019;62:162. doi:10.1007/s11426-018-9392-6
   Web of Science ®Google Scholar
• Min Y, Wang X, Chen H, Chen J, Xiang K, Yin G. Thermal ablation for papillary thyroid microcarcinoma: how far we have come?. Cancer Manag Res. 2020;12:13369–13379. doi:10.2147/CMAR.S287473
   PubMed Web of Science ®Google Scholar
• Hu JJ, Cheng YJ, Zhang XZ. Recent advances in nanomaterials for enhanced photothermal therapy of tumors. Nanoscale. 2018;10(48):22657–22672. doi:10.1039/c8nr07627h
   PubMed Web of Science ®Google Scholar
• Liu X, Qin J, Zhang X, et al. The mechanisms of HSA@PDA/Fe nanocomposites with enhanced nanozyme activity and their application in intracellular H(2)O(2) detection. Nanoscale. 2020;12(47):24206–24213. doi:10.1039/d0nr05732k
   PubMed Web of Science ®Google Scholar
• Huang S, Wu Y, Li C, et al. Tailoring morphologies of mesoporous polydopamine nanoparticles to deliver high-loading radioiodine for anaplastic thyroid carcinoma imaging and therapy. Nanoscale. 2021;13(35):15021–15030. doi:10.1039/d1nr02892h
   PubMed Web of Science ®Google Scholar
• Wang K, Wang S, Chen K, Zhao Y, Ma X, Wang L. Doxorubicin-loaded melanin particles for enhanced chemotherapy in drug-resistant anaplastic thyroid cancer cells. J Nanomater. 2018;2018:1–6.
   Web of Science ®Google Scholar
• Han X, Xu X, Tang Y, et al. BSA-stabilized mesoporous organosilica nanoparticles reversed chemotherapy resistance of anaplastic thyroid cancer by increasing drug uptake and reducing cellular efflux. Front Mol Biosci. 2020;7:610084. doi:10.3389/fmolb.2020.610084
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang R, Tan J, et al. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2. Oncol Rep. 2020;43(5):1491–1502. doi:10.3892/or.2020.7537
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen Y, Adachi M, et al. Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer. Biomaterials. 2015;57:41–49. doi:10.1016/j.biomaterials.2015.04.013
   PubMed Web of Science ®Google Scholar
• Liu Y, Ma Y, Peng X, et al. Cetuximab-conjugated perfluorohexane/gold nanoparticles for low intensity focused ultrasound diagnosis ablation of thyroid cancer treatment. Sci Technol Adv Mater. 2021;21(1):856–866. doi:10.1080/14686996.2020.1855064
   PubMed Web of Science ®Google Scholar
• Nilubol N, Yuan Z, Paciotti GF, et al. Novel dual-action targeted nanomedicine in mice with metastatic thyroid cancer and pancreatic neuroendocrine tumors. J Natl Cancer Inst. 2018;110(9):1019–1029. doi:10.1093/jnci/djy003
   PubMedGoogle Scholar
• Amaral M, Charmier AJ, Afonso RA, et al. Gold-based nanoplataform for the treatment of anaplastic thyroid carcinoma: a step forward. Cancers. 2021;13(6). doi:10.3390/cancers13061242
   Web of Science ®Google Scholar
• Lvov Y, Abdullayev E. Green and functional polymer-clay nanotube composites with sustained release of chemical agents. Prog Polym Sci. 2013;38:1690. doi:10.1016/j.progpolymsci.2013.05.009
   Web of Science ®Google Scholar
• Vergaro V, Lvov YM, Leporatti S. Halloysite clay nanotubes for resveratrol delivery to cancer cells. Macromol Biosci. 2012;12(9):1265–1271. doi:10.1002/mabi.201200121
   PubMed Web of Science ®Google Scholar
• Kelly HM, Deasy PB, Ziaka E, Claffey N. Formulation and preliminary in vivo dog studies of a novel drug delivery system for the treatment of periodontitis. Int J Pharm. 2004;274(1–2):167–183. doi:10.1016/j.ijpharm.2004.01.019
   PubMedGoogle Scholar
• Massaro M, Piana S, Colletti CG, et al. Multicavity halloysite-amphiphilic cyclodextrin hybrids for co-delivery of natural drugs into thyroid cancer cells. J Mater Chem B. 2015;3(19):4074–4081. doi:10.1039/c5tb00564g
   PubMed Web of Science ®Google Scholar
• Casali PG, Trama A. Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU). ESMO Open. 2020;5(2):e000666. doi:10.1136/esmoopen-2019-000666
   PubMed Web of Science ®Google Scholar
• Lai WA, Hang JF, Liu CY, et al. PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50. Virchows Arch. 2020;476(3):431–437. doi:10.1007/s00428-019-02708-4
   PubMed Web of Science ®Google Scholar
• Gule MK, Chen Y, Sano D, et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res. 2011;17(8):2281–2291. doi:10.1158/1078-0432.CCR-10-2762
   PubMed Web of Science ®Google Scholar
• Ding ZY, Huang YJ, Tang JD, Li G, Jiang PQ, Wu HT. Silencing of hypoxia-inducible factor-1alpha promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2. Exp Ther Med. 2016;12(6):3735–3741. doi:10.3892/etm.2016.3826
   PubMed Web of Science ®Google Scholar
• Nakayama M, Okano T. [Drug delivery systems using nano-sized drug carriers]. Gan To Kagaku Ryoho. 2005;32(7):935–940. Japanese.
   PubMedGoogle Scholar
• Ke Y, Xiang C. Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy. Int J Nanomedicine. 2018;13:8339–8354. doi:10.2147/IJN.S187240
   PubMed Web of Science ®Google Scholar
• Zhu R, Wang Z, Liang P, et al. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO(2)@LDH for anti-neuroblastoma therapy. Acta Biomater. 2017;63:163–180. doi:10.1016/j.actbio.2017.09.009
   PubMed Web of Science ®Google Scholar
• Missiaen R, Morales-Rodriguez F, Eelen G, Carmeliet P. Targeting endothelial metabolism for anti-angiogenesis therapy: a pharmacological perspective. Vascul Pharmacol. 2017;90:8–18. doi:10.1016/j.vph.2017.01.001
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20(6):660–673. doi:10.1634/theoncologist.2014-0465
   PubMed Web of Science ®Google Scholar
• Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst. 2000;92(19):1564–1572. doi:10.1093/jnci/92.19.1564
   PubMedGoogle Scholar
• Porter JR, Fritz CC, Depew KM. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol. 2010;14(3):412–420. doi:10.1016/j.cbpa.2010.03.019
   PubMed Web of Science ®Google Scholar
• Kim YS, Alarcon SV, Lee S, et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem. 2009;9(15):1479–1492. doi:10.2174/156802609789895728
   PubMed Web of Science ®Google Scholar
• Ahmed M, Hussain AR, Bavi P, et al. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. Carcinogenesis. 2014;35(7):1564–1572. doi:10.1093/carcin/bgu051
   PubMed Web of Science ®Google Scholar
• Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer. Oncogene. 2013;32(34):3923–3932. doi:10.1038/onc.2012.567
   PubMed Web of Science ®Google Scholar
• Tavares C, Eloy C, Melo M, et al. mTOR pathway in papillary thyroid carcinoma: different contributions of mTORC1 and mTORC2 complexes for tumor behavior and SLC5A5 mRNA Expression. Int J Mol Sci. 2018;19(5):1448. doi:10.3390/ijms19051448
   PubMed Web of Science ®Google Scholar
• Faustino A, Couto JP, Populo H, et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(7):E1139–49. doi:10.1210/jc.2011-2748
   PubMed Web of Science ®Google Scholar
• Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 2014;9(1):1–20. doi:10.2174/15748928113089990031
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen H, Shi J. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater. 2013;25(23):3144–3176. doi:10.1002/adma.201205292
   PubMed Web of Science ®Google Scholar
• Tessier-Cloutier B, Kortekaas KE, Thompson E, et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod Pathol. 2020;33(8):1595–1605. doi:10.1038/s41379-020-0524-1
   PubMed Web of Science ®Google Scholar
• Yoo SK, Song YS, Lee EK, et al. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat Commun. 2019;10(1):2764. doi:10.1038/s41467-019-10680-5
   PubMedGoogle Scholar
• Morgan MA, Lawrence TS. Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways. Clin Cancer Res. 2015;21(13):2898–2904. doi:10.1158/1078-0432.CCR-13-3229
   PubMed Web of Science ®Google Scholar
• Varinelli L, Caccia D, Volpi CC, et al. 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas. Endocr Relat Cancer. 2015;22(5):759–775. doi:10.1530/ERC-15-0299
   PubMed Web of Science ®Google Scholar
• Huang S, Zhang L, Xu M, et al. Co-Delivery of (131) I and prima-1 by self-assembled CD44-targeted nanoparticles for anaplastic thyroid carcinoma theranostics. Adv Healthc Mater. 2021;10(3):e2001029. doi:10.1002/adhm.202001029
   PubMed Web of Science ®Google Scholar
• Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781. doi:10.1016/j.lfs.2019.116781
   PubMed Web of Science ®Google Scholar
• Wang T, Shigdar S, Gantier MP, et al. Cancer stem cell targeted therapy: progress amid controversies. Oncotarget. 2015;6(42):44191–44206. doi:10.18632/oncotarget.6176
   PubMedGoogle Scholar
• Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126(9):2067–2078. doi:10.1002/ijc.24868
   PubMed Web of Science ®Google Scholar
• Cheng JX, Liu BL, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors?. Cancer Treat Rev. 2009;35(5):403–408. doi:10.1016/j.ctrv.2009.03.002
   PubMed Web of Science ®Google Scholar
• Yang ZL, Zheng Q, Yan J, Pan Y, Wang ZG. Upregulated CD133 expression in tumorigenesis of colon cancer cells. World J Gastroenterol. 2011;17(7):932–937. doi:10.3748/wjg.v17.i7.932
   PubMed Web of Science ®Google Scholar
• Ge MH, Zhu XH, Shao YM, et al. Synthesis and characterization of CD133 targeted aptamer-drug conjugates for precision therapy of anaplastic thyroid cancer. Biomater Sci. 2021;9(4):1313–1324. doi:10.1039/d0bm01832e
   PubMed Web of Science ®Google Scholar
• Maggisano V, Celano M, Lombardo GE, et al. Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Mol Cell Endocrinol. 2017;448:34–40. doi:10.1016/j.mce.2017.03.007
   PubMed Web of Science ®Google Scholar
• Takeda T, Inaba H, Yamazaki M, et al. Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J Clin Endocrinol Metab. 2003;88(8):3531–3538. doi:10.1210/jc.2002-021856
   PubMed Web of Science ®Google Scholar
• Shepelev MV, Kalinichenko SV, Saakian EK, Korobko IV. Xenobiotic response elements (XREs) from human CYP1A1 gene enhance the hTERT promoter activity. Dokl Biochem Biophys. 2019;485(1):150–152. doi:10.1134/S1607672919020200
   PubMed Web of Science ®Google Scholar
• Chang A, Ling J, Ye H, Zhao H, Zhuo X. Enhancement of nanoparticle-mediated double suicide gene expression driven by ‘E9-hTERT promoter’ switch in dedifferentiated thyroid cancer cells. Bioengineered. 2021;12(1):6572–6578. doi:10.1080/21655979.2021.1974648
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–199. doi:10.1038/nrc3431
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73(8):2412–2417. doi:10.1158/0008-5472.CAN-12-4561
   PubMed Web of Science ®Google Scholar
• Miller MA, Gadde S, Pfirschke C, et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci Transl Med. 2015;7(314):314ra183. doi:10.1126/scitranslmed.aac6522
   PubMed Web of Science ®Google Scholar
• Arrieta O, Medina LA, Estrada-Lobato E, Ramirez-Tirado LA, Mendoza-Garcia VO, de la Garza-Salazar J. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin. Cancer Chemother Pharmacol. 2014;74(1):211–215. doi:10.1007/s00280-014-2477-x
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature . 2006;440(7083):463–469. doi:10.1038/nature04710
   PubMed Web of Science ®Google Scholar
• Wadhwa S, Wadhwa P, Dinda AK, Gupta NP. Differential expression of potassium ion channels in human renal cell carcinoma. Int Urol Nephrol. 2009;41(2):251–257. doi:10.1007/s11255-008-9459-z
   PubMed Web of Science ®Google Scholar
• Masi A, Becchetti A, Restano-Cassulini R, et al. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer. 2005;93(7):781–792. doi:10.1038/sj.bjc.6602775
   PubMed Web of Science ®Google Scholar
• Pillozzi S, Brizzi MF, Balzi M, et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia. 2002;16(9):1791–1798. doi:10.1038/sj.leu.2402572
   PubMed Web of Science ®Google Scholar
• Li G, Hu Z, Yin H, et al. A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for “smart” small interfering RNA delivery and in vitro antitumor effects by human ether-a-go-go-related gene silencing in anaplastic thyroid carcinoma cells. Int J Nanomedicine. 2013;8:1293–1306. doi:10.2147/IJN.S41555
   PubMed Web of Science ®Google Scholar
• Bartolome RA, Martin-Regalado A, Jaen M, et al. Protein tyrosine phosphatase-1B inhibition disrupts IL13Ralpha2-Promoted invasion and metastasis in cancer cells. Cancers. 2020;12(2):500. doi:10.3390/cancers12020500
   PubMed Web of Science ®Google Scholar
• Gu M. IL13Ralpha2 siRNA inhibited cell proliferation, induced cell apoptosis, and suppressed cell invasion in papillary thyroid carcinoma cells. Onco Targets Ther. 2018;11:1345–1352. doi:10.2147/OTT.S153703
   PubMed Web of Science ®Google Scholar
• Tabeshpour J, Mehri S, Shaebani Behbahani F, Hosseinzadeh H. Protective effects of Vitis vinifera (grapes) and one of its biologically active constituents, resveratrol, against natural and chemical toxicities: a comprehensive review. Phytother Res. 2018;32(11):2164–2190. doi:10.1002/ptr.6168
   PubMed Web of Science ®Google Scholar
• Xiong L, Lin XM, Nie JH, Ye HS, Liu J. Resveratrol and its nanoparticle suppress doxorubicin/docetaxel-resistant anaplastic thyroid cancer cells in vitro and in vivo. Nanotheranostics. 2021;5(2):143–154. doi:10.7150/ntno.53844
   PubMedGoogle Scholar
• Ravera S, Reyna-Neyra A, Ferrandino G, Amzel LM, Carrasco N. The Sodium/Iodide Symporter (NIS): molecular physiology and preclinical and clinical applications. Annu Rev Physiol. 2017;79:261–289. doi:10.1146/annurev-physiol-022516-034125
   PubMed Web of Science ®Google Scholar
• Schmohl KA, Dolp P, Schug C, et al. Reintroducing the sodium-iodide symporter to anaplastic thyroid carcinoma. Thyroid. 2017;27(12):1534–1543. doi:10.1089/thy.2017.0290
   PubMed Web of Science ®Google Scholar
• Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–1066. doi:10.1172/JCI85271
   PubMed Web of Science ®Google Scholar
• Raeesi V, Chan WC. Improving nanoparticle diffusion through tumor collagen matrix by photo-thermal gold nanorods. Nanoscale. 2016;8(25):12524–12530. doi:10.1039/c5nr08463f
   PubMed Web of Science ®Google Scholar
• Ku G, Zhou M, Song S, Huang Q, Hazle J, Li C. Copper sulfide nanoparticles as a new class of photoacoustic contrast agent for deep tissue imaging at 1064 nm. ACS Nano. 2012;6(8):7489–7496. doi:10.1021/nn302782y
   PubMed Web of Science ®Google Scholar
• Li S, Zhang D, Sheng S, Sun H. Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles. Int J Nanomedicine. 2017;12:5993–6003. doi:10.2147/IJN.S137335
   PubMed Web of Science ®Google Scholar
• Qian CG, Chen YL, Feng PJ, et al. Conjugated polymer nanomaterials for theranostics. Acta Pharmacol Sin. 2017;38(6):764–781. doi:10.1038/aps.2017.42
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Khalansky AS, Gelperina S, et al. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One. 2011;6(5):e19121. doi:10.1371/journal.pone.0019121
   PubMed Web of Science ®Google Scholar
• Gigliotti CL, Ferrara B, Occhipinti S, et al. Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors. Drug Deliv. 2017;24(1):670–680. doi:10.1080/10717544.2017.1303856
   PubMed Web of Science ®Google Scholar
• Brierley J, Sherman E. The role of external beam radiation and targeted therapy in thyroid cancer. Semin Radiat Oncol. 2012;22(3):254–262. doi:10.1016/j.semradonc.2012.03.010
   PubMed Web of Science ®Google Scholar
• Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380–387. doi:10.1038/nrc1071
   PubMed Web of Science ®Google Scholar
• Kim H, Kim SW, Seok KH, et al. Hypericin-assisted photodynamic therapy against anaplastic thyroid cancer. Photodiagnosis Photodyn Ther. 2018;24:15–21. doi:10.1016/j.pdpdt.2018.08.008
   PubMed Web of Science ®Google Scholar
• Wang HZ, Zhang Y, Xie LP, Yu XY, Zhang RQ. Effects of genistein and daidzein on the cell growth, cell cycle, and differentiation of human and murine melanoma cells(1). J Nutr Biochem. 2002;13(7):421–426. doi:10.1016/s0955-2863(02)00184-5
   PubMed Web of Science ®Google Scholar
• Chodon D, Ramamurty N, Sakthisekaran D. Preliminary studies on induction of apoptosis by genistein on HepG2 cell line. Toxicol In Vitro. 2007;21(5):887–891. doi:10.1016/j.tiv.2007.01.023
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu J, Li X, Li JC. PCDH17 gene promoter demethylation and cell cycle arrest by genistein in gastric cancer. Histol Histopathol. 2012;27(2):217–224. doi:10.14670/HH-27.217
   PubMed Web of Science ®Google Scholar
• Ahn JC, Biswas R, Chung PS. Combination with genistein enhances the efficacy of photodynamic therapy against human anaplastic thyroid cancer cells. Lasers Surg Med. 2012;44(10):840–849. doi:10.1002/lsm.22095
   PubMed Web of Science ®Google Scholar
• Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer. 2010;62(1):1–20. doi:10.1080/01635580903191585
   PubMed Web of Science ®Google Scholar
• Buhklari S, Memon S, Tahir MM, Bhanjer MI. Synthesis, characterization and investigation of antioxidant activity of cobalt–quercetin complex. J Mol Struct. 2008;892:39–46. doi:10.1016/j.molstruc.2008.04.050
   Web of Science ®Google Scholar
• Wei Y, Ye XL, Shang XG, et al.. Enhanced oral bioavailability of silybin by a supersaturatable self-emulsifying drug delivery system (S-SEDDS). Colloids Surf A. 2012;396:22–28. doi:10.1016/j.colsurfa.2011.12.025
   Web of Science ®Google Scholar
• Yu T, Tong L, Ao Y, Zhang G, Liu Y, Zhang H. Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy. J Photochem Photobiol B. 2019;197:111534. doi:10.1016/j.jphotobiol.2019.111534
   PubMed Web of Science ®Google Scholar
• Janssen EM, Dy SM, Meara AS, Kneuertz PJ, Presley CJ, Bridges JFP. Analysis of patient preferences in lung cancer - estimating acceptable tradeoffs between treatment benefit and side effects. Patient Prefer Adherence. 2020;14:927–937. doi:10.2147/PPA.S235430
   PubMed Web of Science ®Google Scholar
• Xu M, Yim W, Zhou J, et al. The application of organic nanomaterials for bioimaging, drug delivery, and therapy. IEEE Nanotechnol Mag. 2021;15(4):8–28. doi:10.1109/MNANO.2021.3081758
   Web of Science ®Google Scholar
• Lechuga-Islas VD, Trejo-Maldonado M, Anufriev I, et al. All-aqueous, surfactant-free, and pH-driven nanoformulation methods of dual-responsive polymer nanoparticles and their potential use as nanocarriers of pH-sensitive drugs. Macromol Biosci. 2023;23(1):e2200262. doi:10.1002/mabi.202200262
   PubMed Web of Science ®Google Scholar
• Deng C, Zhao J, Zhou S, et al. The vascular disrupting agent CA4P improves the antitumor efficacy of CAR-T cells in preclinical models of solid human tumors. Mol Ther. 2020;28(1):75–88. doi:10.1016/j.ymthe.2019.10.010
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Li M, Lin J, et al. Preliminary study on the sequencing of whole genomic methylation and transcriptome-related genes in thyroid carcinoma. Cancers. 2022;14(5). doi:10.3390/cancers14051163
   Web of Science ®Google Scholar
• Chudasama V. Antibody - Drug conjugates (ADC) - Drug discovery today: technologies. Drug Discov Today Technol. 2018;30:1–2. doi:10.1016/j.ddtec.2018.11.003
   PubMedGoogle Scholar
• Lee S, Oudjedi F, Kirk A, Paliouras M, Trifiro M. Photothermal therapy of papillary thyroid cancer tumor xenografts with targeted thyroid stimulating hormone receptor antibody functionalized multiwalled carbon nanotubes. Cancer Nanotechnol. 2023;14(1). doi:10.1186/s12645-023-00184-9
   Web of Science ®Google Scholar
• Yu Y, Li J, Song B, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2022;280:121312. doi:10.1016/j.biomaterials.2021.121312
   PubMed Web of Science ®Google Scholar
• Liang J, Jin Z, Kuang J, et al. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer. 2021;125(3):390–401. doi:10.1038/s41416-021-01340-x
   PubMed Web of Science ®Google Scholar
• Yin M, Di G, Bian M. Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer. Int Immunopharmacol. 2018;64:333–339. doi:10.1016/j.intimp.2018.09.016
   PubMed Web of Science ®Google Scholar